Susanna Naggie, MD

Professor of Medicine
Vice Dean for Clinical Research
Member in the Duke Clinical Research Institute
Campus mail 300 West Morgan St, Suite 800, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Kohli, Anita, Susanna Naggie, Michael A. Polis, Henry Masur, and Shyam Kottilil. “HIV/HCV-COINFECTED NATURAL VIRAL SUPPRESSORS HAVE BETTER VIROLOGIC RESPONSES TO PEG-IFN AND RIBAVIRIN THAN ARV-TREATED HIV/HCV PATIENTS.” In Hepatology, 54:847A-847A. WILEY-BLACKWELL, 2011.

Scholars@Duke

Sidique, Nadeera, Anita Kohli, Bhavana Shivakumar, Stephen Migueles, G Mani Subramanian, Susanna Naggie, Michael A. Polis, Henry Masur, and Shyam Kottilil. “HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.” J Acquir Immune Defic Syndr 58, no. 2 (October 1, 2011): e38–40. https://doi.org/10.1097/QAI.0b013e31822d463f.

PMID
21921725
Full Text

Gellad, Ziad F., Susanna Naggie, Shelby D. Reed, Paul J. Clark, Alex J. Thompson, Kevin A. Schulman, and Andrew J. Muir. “THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM.” In Hepatology, 54:417A-418A. WILEY-BLACKWELL, 2011.

Scholars@Duke

Clark, Paul J., Alexander J. Thompson, Thomas J. Urban, Keyur Patel, David M. Vock, Qianqian Zhu, Alison Jazwinski, et al. “PNPLA3 GENOTYPE RATHER THAN RACE MAY EXPLAIN THE LOWER PREVALENCE OF HEPATIC STEATOSIS DESPITE WORSE METABOLIC RISK FACTORS IN AFRICAN AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (CHC).” In Hepatology, 54:402A-402A. WILEY-BLACKWELL, 2011.

Scholars@Duke

Thompson, Alexander J., Paul J. Clark, Hans L. Tillmann, Keyur Patel, Susanna Naggie, F Fred Poordad, Eric Lawitz, et al. “= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS.” In Hepatology, 54:436A-437A. WILEY-BLACKWELL, 2011.

Scholars@Duke

Barreiro, Pablo, Juan Antonio Pineda, Norma Rallón, Susanna Naggie, Luz Martín-Carbonero, Karin Neukam, Antonio Rivero, et al. “Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.” J Infect Dis 203, no. 11 (June 1, 2011): 1629–36. https://doi.org/10.1093/infdis/jir113.

PMID
21592993
Full Text

Rallón, Norma I., Vincent Soriano, Susanna Naggie, Clara Restrepo, David Goldstein, Eugenia Vispo, John McHutchison, and José M. Benito. “IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.” Aids 25, no. 8 (May 15, 2011): 1025–33. https://doi.org/10.1097/QAD.0b013e3283471cae.

PMID
21505315
Full Text

Jazwinski, Alison, Susanna Naggie, and John Perfect. “Immune reconstitution syndrome in a patient with disseminated histoplasmosis and steroid taper: maintaining the perfect balance.” Mycoses 54, no. 3 (May 2011): 270–72. https://doi.org/10.1111/j.1439-0507.2009.01796.x.

PMID
19843232
Full Text

Naggie, S. N. “Investigational Agents for Chronic Viral Infections: HIV and HCV.” Journal of Neuroimmune Pharmacology 6 (April 1, 2011): S18–S18.

Scholars@Duke

Naggie, Susanna, Becky A. Miller, Kimberly B. Zuzak, Brian W. Pence, Ashley J. Mayo, Bradly P. Nicholson, Preeta K. Kutty, L Clifford McDonald, and Christopher W. Woods. “A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.” Am J Med 124, no. 3 (March 2011): 276.e1-276.e7. https://doi.org/10.1016/j.amjmed.2010.10.013.

PMID
21396512
Full Text

Pages